January 15, 2024 – A2A Pharmaceuticals has announced the dosing of the first patient in their Phase I trial for AO-252, a novel TACC3 PPI inhibitor. This trial will evaluate the safety and efficacy of AO-252 in patients with various cancers, including triple-negative breast cancer, high-grade serious ovarian cancer, and endometrial cancers. AO-252, developed using A2A’s proprietary SCULPT™ System, has shown promising preclinical results, and this trial marks a significant milestone in its development.
